Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J.

Br J Haematol. 2002 Feb;116(2):278-90.

PMID:
11841428
2.
3.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC.

Blood. 2007 Sep 1;110(5):1656-63. Epub 2007 May 17.

4.

Cancer and the microenvironment: myeloma-osteoclast interactions as a model.

Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J.

Cancer Res. 2004 Mar 15;64(6):2016-23.

6.

Antimyeloma efficacy of thalidomide in the SCID-hu model.

Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J.

Blood. 2002 Dec 1;100(12):4162-8. Epub 2002 Aug 8.

7.

The development of a model for the homing of multiple myeloma cells to human bone marrow.

Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC.

Blood. 1997 Jul 15;90(2):754-65.

8.

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.

Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, Croucher PI.

Cancer Res. 2007 Jan 1;67(1):202-8.

9.

The SCID-hu myeloma model.

Epstein J, Yaccoby S.

Methods Mol Med. 2005;113:183-90.

PMID:
15968103
10.

Development of an in vivo model of human multiple myeloma bone disease.

Alsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR, Roodman GD.

Blood. 1996 Feb 15;87(4):1495-501.

11.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

12.

Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.

Hayashi S, Yamada T, Tsuneto M, Yamane T, Takahashi M, Shultz LD, Yamazaki H.

J Immunol. 2003 Nov 15;171(10):5130-9.

13.

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.

Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ.

Blood. 2004 Mar 15;103(6):2308-15. Epub 2003 Nov 13.

14.

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hideshima T, Shringarpure R, Shi J, Allam CK, Wijdenes J, Venuta S, Munshi NC, Anderson KC.

Blood. 2004 Dec 1;104(12):3688-96. Epub 2004 Aug 3.

15.

RANK ligand and osteoprotegerin in myeloma bone disease.

Sezer O, Heider U, Zavrski I, K├╝hne CA, Hofbauer LC.

Blood. 2003 Mar 15;101(6):2094-8. Epub 2002 Nov 7. Review.

16.

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.

Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC.

Clin Cancer Res. 2005 Jun 1;11(11):4251-8.

18.

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Croucher PI, Shipman CM, Van Camp B, Vanderkerken K.

Cancer. 2003 Feb 1;97(3 Suppl):818-24.

19.

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.

Cancer Res. 2007 May 15;67(10):4572-7. Epub 2007 May 10.

20.

KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.

Miki H, Ozaki S, Nakamura S, Oda A, Amou H, Ikegame A, Watanabe K, Hiasa M, Cui Q, Harada T, Fujii S, Nakano A, Kagawa K, Takeuchi K, Yata K, Sakai A, Abe M, Matsumoto T.

Br J Haematol. 2011 Nov;155(3):328-39. doi: 10.1111/j.1365-2141.2011.08844.x. Epub 2011 Sep 9.

PMID:
21902681

Supplemental Content

Support Center